HKEx chief executive Charles Li on the wave of pre-revenue biotech companies from China that will be permitted to list on Hong Kong’s stock exchange. Bankers say there are about 10 biotech firms keen to float. About 800 new molecules are either under trial or in pre-trial testing in China, up from 240 in 2012, the Financial Times has reported.
© ChinTell Ltd. All rights reserved.
Exclusively sponsored by HSBC.
The Week in China website and the weekly magazine publications are owned and maintained by ChinTell Limited, Hong Kong. Neither HSBC nor any member of the HSBC group of companies ("HSBC") endorses the contents and/or is involved in selecting, creating or editing the contents of the Week in China website or the Week in China magazine. The views expressed in these publications are solely the views of ChinTell Limited and do not necessarily reflect the views or investment ideas of HSBC. No responsibility will therefore be assumed by HSBC for the contents of these publications or for the errors or omissions therein.